Rincon lithium project: US$2.5bn cost, 60,000tpa capacity, DLE technology and 2028 production timeline
Read More Pharma Industry News Can Matinas BioPharma (MTNB) avoid delisting while trying to salvage MAT2203? Matinas BioPharma faces NYSE American non-compliance over equity levels. Read what it means for MTNB, MAT2203, funding options, and delisting risk. byVenkateshApril 5, 2026